CD8A and cancer: PD−1/PD−L1 blockade has emerged as a novel and promising therapeutic strategy [34], emphasizing the importance of anti−tumor immunity and normalizing cytotoxic T lymphocyte (CTLs, CD8+) dysfunction in cancers [35].